Mrs Brenda Shanahan

BEc, BCom

Non-Executive Director

Mrs Shanahan has a longstanding background in finance in Australian and overseas’ economies and share markets and is a Fellow of the Institute of Directors. She is currently Chair of St Vincent's Medical Research Institute in Melbourne, a non-executive Director of DMP Asset Management, a non-executive Director of Challenger Limited (ASX:CGF) and a Director of the Kimberley Foundation of Australia. Mrs Shanahan is the former Chair of Challenger Listed Investments Ltd, the reporting entity for Challenger Kenedix Japan Trust (ASX:CKT), Challenger Infrastructure Fund (ASX:CIF), Challenger Diversified Property Group (ASX: CDI) and Challenger Wine Trust (ASX:CWT).

She is a former member of the Australian Stock Exchange and former executive director of a stockbroking firm, a fund management company and an actuarial company. Mrs Shanahan is well known in the business and financial community; her insights add significant value to the current Board and the company. Mrs Shanahan was Non-Executive Chair of the CLINUVEL Board from late 2007 until July 2010.

Latest Company Announcements

19 September 2017


CLINUVEL PHARMACEUTICALS LTD today announced an update on its submission of the New Drug Application (NDA) for CLINUVEL’s drug SCENESSE® (afamelanotide 16 mg) to the US Food and Drug Administration (FDA).

Read More
06 September 2017

Appendix 3B

Appendix 3B - New issue announcement

Read More
30 August 2017

Appendix 4E - Preliminary Final Report 2016/17

Appendix 4E - Preliminary Final Report 2016/17

Read More
08 August 2017

Form 604, 09 August 2017

Notice of change of interests of substantial holder

Read More
31 July 2017

Appendix 4C - Quarterly report

Appendix 4C

Read More
25 July 2017

CLINUVEL Newsletter - July 2017

For those who have followed the Company over the years, the journey of our teams has most often been counter-current to arrive at the present point.

Read More

Quick Links